Schizophrenia reduced by biweekly 50,000 IU Vitamin D and probiotics – RCT Feb 2019

Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients

BMC Psychiatry 201919:77, https://doi.org/10.1186/s12888-019-2059-x

VitaminDWiki

Note: nice results with a small amount of Vitamin D
50,000 IU Vitamin D bi-weekly was not enough to get the average blood level to 30 ng
Anticipate far better results in patients getting weekly 50,000 IU

Suspect that the probiotic just increased the Vitamin D bio-availability, which is poor in those with poor guts
There are several forms of gut-friendly Vitamin D which might not need probiotics

Overview Schizophrenia and Vitamin D contains the following summary

14 reasons to think that schizophrenia is associated with low vitamin D
1) 97% of patients with schizophrenia are vitamin D deficient
2) Schizophrenia varies with latitude (UVB) by 10X (controversy)
3) Schizophrenia is more common in those with dark skin (when away from the equator)
4) Schizophrenia is associated with low natal vitamin D
5) Schizophrenia has been increasing around the world when vitamin D has been decreasing (controversy)
6) Schizophrenia is associated with low birth rate, which is associated with low vitamin D
7) Schizophrenia is associated with Autism which is associated with low vitamin D
8) Schizophrenia Bulletin Editorial (Jan 2014) speculated that Vitamin D could be a major player
9) Schizophrenia 2X more likely if low vitamin D - meta-analysis
10) Schizophrenia increased 40 % for Spring births after Danes stopped vitamin D fortification
11) Schizophrenia is associated with season of birth
12) Schizophrenia is associated with poor Vitamin D Receptor genes
13) Schizophrenia risk is decreased if give Vitamin D after birth
14) Schizophrenia symptoms reduced when Vitamin D levels are restored


Omega-3 also helps Schizophrenia

B12 and Schizophrenia

Probiotics

See also web

  • Probiotics improve cognition in Alzheimer's patients RCT Nov 2016
    Nothing about Vitamin D. 12 weeks of probiotics for Alzheimer's patients increased mental test score from 8.7 to 10.6 (max score =30)
  • Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study - May 2017
    10.1016/j.bbi.2016.11.019, Free PDF
  • The microbiome, immunity, and schizophrenia and bipolar disorder - May 2017
    doi: 10.1016/j.bbi.2016.12.010, Free PDF
  • Gastroenterology issues in schizophrenia: why the gut matters| May 2017
    doi: 10.1007/s11920-015-0574-0, Free PDF
  • The Microbiome: A New Target for Research and Treatment of Schizophrenia and its Resistant Presentations? A Systematic Literature Search and Review
    Oct 2018, doi: 10.3389/fphar.2018.01040, Free PDF
  • Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects
    Sept 2018, doi: 10.1016/j.schres.2018.09.014
  • The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option
    Sept 2017 , Free PDF
  • The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments
    2018, doi: 10.2174/1570159X15666170915141036, Free PDF

 Download the PDF from VitaminDWiki
Image
This is just the top of a long table in the PDF

Background: This study determined the effects of a novel combination of vitamin D and probiotic on metabolic and clinical symptoms in chronic schizophrenia.

Methods: This trial was conducted among 60 patients with chronic schizophrenia to receive either 50,000 IU vitamin D3 every 2 weeks plus 8 × 109 CFU/day probiotic (n = 30) or placebo (n = 30) for 12 weeks.

Results
Vitamin D and probiotic co-supplementation was associated with a significant improvement in the general (− 3.1 ± 4.7 vs. + 0.3 ± 3.9, P = 0.004) and total PANSS scores (− 7.4 ± 8.7 vs. -1.9 ± 7.5, P = 0.01). Vitamin D and probiotic co-supplementation also significantly increased total antioxidant capacity (+ 51.1 ± 129.7 vs. -20.7 ± 53.3 mmol/L, P = 0.007), and significantly decreased malondialdehyde (− 0.3 ± 0.9 vs. + 0.2 ± 0.4 μmol/L, P = 0.01) and high sensitivity C-reactive protein levels (− 2.3 ± 3.0 vs. -0.3 ± 0.8 mg/L, P = 0.001) compared with the placebo. Moreover, taking vitamin D plus probiotic significantly reduced fasting plasma glucose (− 7.0 ± 9.9 vs. -0.2 ± 9.9 mg/dL, P = 0.01), insulin concentrations (− 2.7 ± 2.3 vs. + 0.4 ± 2.0 μIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (− 0.8 ± 0.7 vs. + 0.1 ± 0.7, P < 0.001), triglycerides (− 7.8 ± 25.2 vs. + 10.1 ± 30.8 mg/dL, P = 0.01) and total cholesterol levels (− 4.9 ± 15.0 vs. + 5.9 ± 19.5 mg/dL, P = 0.04) and total−/HDL-cholesterol ratio (− 0.1 ± 0.6 vs. + 0.3 ± 0.8, P = 0.04).

Conclusion: Probiotic and vitamin D for 12 weeks to chronic schizophrenia had beneficial effects on the general and total PANSS score, and metabolic profiles.

Trial Registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical trials registration (http://www.irct.ir: IRCT2017072333551N2). 07-31-2017 2

9952 visitors, last modified 21 Feb, 2019,
Printer Friendly Follow this page for updates